SCHEDULE: Trails Edge Capital Discloses 9.9% Stake in vTv Therapeutics

Trails Edge Capital Partners, LP and affiliates have reported a 9.9% passive ownership stake in vTv Therapeutics Inc. common stock.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai (collectively, 'Filers') have reported beneficial ownership of 340,536 shares of vTv Therapeutics Inc. common stock.
• This represents 9.9% of the outstanding common stock of vTv Therapeutics Inc.
• The ownership includes 231,000 shares held directly by Trails Edge Biotechnology and 109,536 shares underlying prefunded warrants.
• The Filers also hold additional prefunded warrants (314,835 shares) and common warrants (655,371 shares) which are subject to an issuance limitation preventing ownership from exceeding 9.99% of outstanding shares upon exercise.
• The ownership percentage is calculated based on 2,617,215 shares outstanding as of August 12, 2025, plus 682,018 shares issued subsequently.
• The investment is stated to be for passive purposes, not to change or influence control of the issuer, except for potential nomination activities under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized investment firm is generally viewed as a positive signal, indicating investor confidence in the company's value or future prospects, even if the intent is passive.

Positives

• A significant stake by an institutional investor like Trails Edge Capital Partners can signal confidence in vTv Therapeutics' future prospects.
• The investment firm's expertise in biotechnology (Trails Edge Biotechnology Master Fund) suggests a strategic interest in the company's sector.

Risks

• The beneficial ownership is capped at 9.99% due to warrant issuance limitations, which restricts the Filers' ability to increase their stake through warrant exercise beyond this threshold without further disclosures or potential changes in investment intent.

Future Outlook

NA

Industry Context

The acquisition of a significant stake by a specialized biotechnology investment fund like Trails Edge Biotechnology Master Fund suggests a belief in the long-term potential of vTv Therapeutics, a company operating in the biotechnology sector. Such investments are common as funds seek to capitalize on growth opportunities within specific industries.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor may provide a degree of stability and validation for other shareholders.
• Company Management: Awareness of a large passive investor may influence strategic decisions, though the stated intent is not to influence control.

Key Dates

Recommendation

While the disclosure of a significant passive stake by a reputable investment firm like Trails Edge Capital Partners can be seen as a positive indicator of confidence in vTv Therapeutics, a Schedule 13G filing itself does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. The investment is stated as passive, limiting direct influence. Investors should 'hold' and await further operational updates or financial reports from vTv Therapeutics to make a more informed decision.

Keywords

vTv Therapeutics, Trails Edge Capital Partners, Schedule 13G, common stock, beneficial ownership, institutional investor, biotechnology, passive investment, warrants, SEC filing